Virtus Biotech ETF
14 hedge funds and large institutions have $3.89M invested in Virtus Biotech ETF in 2022 Q3 according to their latest regulatory filings, with 4 funds opening new positions, 2 increasing their positions, 6 reducing their positions, and 0 closing their positions.
27% more funds holding
Funds holding: 11 → 14 (+3)
9% more capital invested
Capital invested by funds: $3.58M → $3.89M (+$315K)
0.24% less ownership
Funds ownership: 24.77% → 24.53% (-0.24%)
67% less repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 6
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Rockefeller Capital Management
New York
|
+$1.27M |
| 2 |
Stifel Financial
St. Louis,
Missouri
|
+$271K |
| 3 |
LPL Financial
San Diego,
California
|
+$217K |
| 4 |
Morgan Stanley
New York
|
+$25.8K |
| 5 |
Carson Wealth (CWM LLC)
Omaha,
Nebraska
|
+$13.9K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
-$1.31M |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$82.2K |
| 3 |
Citadel Advisors
Miami,
Florida
|
-$43.9K |
| 4 |
UBS Group
Zurich,
Switzerland
|
-$28.3K |
| 5 |
FWM
Focused Wealth Management
Newburgh,
New York
|
-$9.23K |
BBP Hedge Fund Activity: Q3 2022 in Review
14 of the 5,805 institutional investors tracked by Wall St. Rank reported a position in Virtus Biotech ETF (BBP) for Q3 2022, worth a combined $3.89M — up 8.8% from $3.58M a quarter earlier.
Buyers outnumbered sellers: 4 funds opened new BBP positions and 0 closed out — a net gain of 4 holders — while 2 added to existing stakes and 6 trimmed.
The largest buyer was Rockefeller Capital Management, opening a new position worth an estimated $1.27M. The largest seller was Royal Bank of Canada, cutting an estimated $1.31M.
- 14 institutional investors held Virtus Biotech ETF (BBP) as of Q3 2022, up from 11 in Q2 2022.
- Funds reported $3.89M of Virtus Biotech ETF stock for Q3 2022, up 8.8% quarter-over-quarter.
- 4 funds opened new Virtus Biotech ETF positions in Q3 2022 and 0 closed out, a net change of +4 holders.
- The largest Virtus Biotech ETF buyer in Q3 2022 was Rockefeller Capital Management, an estimated $1.27M added.
- The largest Virtus Biotech ETF seller in Q3 2022 was Royal Bank of Canada, an estimated $1.31M sold.
Based on aggregated 13F filings for Q3 2022.